Similarly, the Society of Surgical Oncology recommends against routine SLNB in cN (−), HR-positive and HER2-negative breast cancer patients aged 70 years or older [26] (https://www.choosingwisely.org/). This evidence concerns the gene ERBB2 and breast carcinoma.